These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction. Sun SX; Ye X; Lee KY; Dupclay L; Plauschinat C Clin Ther; 2008; 30 Pt 2():2217-27. PubMed ID: 19281916 [TBL] [Abstract][Full Text] [Related]
5. Long-term persistence to mono and combination therapies with angiotensin converting enzymes and angiotensin II receptor blockers in Australia. Gadzhanova S; Roughead EE; Bartlett LE Eur J Clin Pharmacol; 2016 Jun; 72(6):765-71. PubMed ID: 26961086 [TBL] [Abstract][Full Text] [Related]
6. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option. Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075 [TBL] [Abstract][Full Text] [Related]
7. Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial. Christian JB; Lapane KL; Hume AL; Eaton CB; Weinstock MA; J Natl Cancer Inst; 2008 Sep; 100(17):1223-32. PubMed ID: 18728281 [TBL] [Abstract][Full Text] [Related]
8. Uptake of angiotensin II receptor blockers in the treatment of hypertension. Greving JP; Denig P; van der Veen WJ; Beltman FW; Sturkenboom MC; de Zeeuw D; Haaijer-Ruskamp FM Eur J Clin Pharmacol; 2005 Jul; 61(5-6):461-6. PubMed ID: 15912393 [TBL] [Abstract][Full Text] [Related]
9. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and the risk of developing rheumatoid arthritis in antihypertensive drug users. de Jong HJ; Vandebriel RJ; Saldi SR; van Dijk L; van Loveren H; Cohen Tervaert JW; Klungel OH Pharmacoepidemiol Drug Saf; 2012 Aug; 21(8):835-43. PubMed ID: 22674737 [TBL] [Abstract][Full Text] [Related]
11. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? Weir MR Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185 [TBL] [Abstract][Full Text] [Related]
12. Angiotensin II type 1 receptor blockade: high hopes sent back to reality? Grothusen A; Divchev D; Luchtefeld M; Schieffer B Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847 [TBL] [Abstract][Full Text] [Related]
13. Use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and lipid-lowering therapies among Rhode Islanders with diabetes enrolled in Medicare Part D plans in 2006 and 2007. Kogut S; Caffrey A; Pezzullo L Med Health R I; 2009 Nov; 92(11):373-6. PubMed ID: 19999898 [No Abstract] [Full Text] [Related]
14. Pharmacological treatment after acute myocardial infarction from 2001 to 2006: a survey in Italian primary care. Filippi A; D'Ambrosio G; Giustini SE; Pecchioli S; Mazzaglia G; Cricelli C J Cardiovasc Med (Hagerstown); 2009 Sep; 10(9):714-8. PubMed ID: 19465867 [TBL] [Abstract][Full Text] [Related]
15. Antihypertensive persistence and drug class. Marentette MA; Gerth WC; Billings DK; Zarnke KB Can J Cardiol; 2002 Jun; 18(6):649-56. PubMed ID: 12107422 [TBL] [Abstract][Full Text] [Related]
16. Parabolas of medication use and discontinuation after myocardial infarction--are we closing the treatment gap? Hudson M; Richard H; Pilote L Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):773-85. PubMed ID: 17486661 [TBL] [Abstract][Full Text] [Related]
17. Discharge use of angiotensin receptor blockers provides comparable effects with angiotensin-converting enzyme inhibitors on outcomes in patients hospitalized for heart failure. Tsuchihashi-Makaya M; Furumoto T; Kinugawa S; Hamaguchi S; Goto K; Goto D; Yamada S; Yokoshiki H; Takeshita A; Tsutsui H; Hypertens Res; 2010 Mar; 33(3):197-202. PubMed ID: 19960016 [TBL] [Abstract][Full Text] [Related]
18. Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence. Simpson E; Beck C; Richard H; Eisenberg MJ; Pilote L Am Heart J; 2003 Mar; 145(3):438-44. PubMed ID: 12660666 [TBL] [Abstract][Full Text] [Related]
19. Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes. Winkelmayer WC; Fischer MA; Schneeweiss S; Wang PS; Levin R; Avorn J Am J Kidney Dis; 2005 Dec; 46(6):1080-7. PubMed ID: 16310574 [TBL] [Abstract][Full Text] [Related]
20. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]